Sylvester Comprehensive Cancer Center

  • 20220824 - Dawar Richa

  • Investigator:
    Richa Dawar
    RCname Email

    Coordinator:

    IRB: 20220824

    SDG: Thoracic
    Disease Site(s):

    Lung

    Sponsor: ETCTN

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination with Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer

    Eligibility Criteria - NCT05198830 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230915 - Lopes Gilberto

  • Investigator:
    Gilberto Lopes
    RCname Email

    Coordinator:

    IRB: 20230915

    SDG: Thoracic
    Disease Site(s):

    Lung,Non-Hodgkin Lymphoma

    Sponsor: Nuvalent

    Enrolling Sites:

    ABLEH
    Aventura
    Gables
    Sylvester

    Title:

    A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)

    Eligibility Criteria - NCT05384626 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230512 - Rodriguez Estelamari

  • Investigator:
    Estelamari Rodriguez
    RCname Email

    Coordinator:

    IRB: 20230512

    SDG: Thoracic
    Disease Site(s):

    Lung

    Sponsor: MERCK SHARP & DOHME

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than

    Eligibility Criteria - NCT05609968 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230700 - Rodriguez Estelamari

  • Investigator:
    Estelamari Rodriguez
    RCname Email

    Coordinator:

    IRB: 20230700

    SDG: Thoracic
    Disease Site(s):

    Lung

    Sponsor: SWOG

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Plantation
    Sylvester

    Title:

    S2302, Pragmatica - Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cel

    Eligibility Criteria - NCT05633602 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231091 - Rodriguez Estelamari

  • Investigator:
    Estelamari Rodriguez
    RCname Email

    Coordinator:

    IRB: 20231091

    SDG: Thoracic
    Disease Site(s):

    Lung

    Sponsor: Summit Therapeutics

    Enrolling Sites:

    Aventura
    Coral Springs
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester

    Title:

    A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment (HARMONi)

    Eligibility Criteria - NCT05184712 *This information has been extracted from " www.clinicaltrials.gov"